- In September 2024, a team led by Mayo Clinic (including Zhao‑Fleming, Dubey, Zekeridou, and Pittock) published a comprehensive analysis introducing the PNS‑CARE diagnostic criteria, a standardized scoring system to improve accuracy in diagnosing Paraneoplastic Neurologic Syndromes. This milestone enhances diagnostic consistency in clinical practice and research.
- In April 2024, Mohamed Rezk and colleagues identified SKOR2‑IgG as a novel biomarker for PNS, enabling earlier diagnosis and better distinction from other neurologic syndromes. This discovery strengthens Mayo Clinic’s biomarker-led precision medicine efforts.
- In June 2024, Frontiers in Immunology published a study detailing clinical characteristics and immunotherapy response in PNS patients, revealing correlations between high‑risk autoantibody profiles and therapeutic outcomes. This provides pivotal insights for tailoring immunotherapy.
- In 2024, Thermo Fisher Scientific launched advanced multiplex immunoassay panels (e.g., ProcartaPlex Luminex panels) designed to detect multiple onconeural and neuroinflammation markers from CSF and plasma—streamlining biomarker profiling in PNS research
